Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Resistance to Proteasome Inhibitors in Cancer by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319067520
Publisher: Springer International Publishing Publication: September 16, 2014
Imprint: Springer Language: English
Author:
ISBN: 9783319067520
Publisher: Springer International Publishing
Publication: September 16, 2014
Imprint: Springer
Language: English

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

More books from Springer International Publishing

Cover of the book Poland in the Irish Nationalist Imagination, 1772–1922 by
Cover of the book Organized Crime, Corruption and Crime Prevention by
Cover of the book Data Science and Big Data Computing by
Cover of the book The New Ottoman Greece in History and Fiction by
Cover of the book Industrial Applications for Intelligent Polymers and Coatings by
Cover of the book Advances in Intelligent, Interactive Systems and Applications by
Cover of the book VipIMAGE 2017 by
Cover of the book Information and Communication Technologies for Ageing Well and e-Health by
Cover of the book Histories of Post-Mortem Contagion by
Cover of the book Modeling Discrete Competitive Facility Location by
Cover of the book Empathy in Health Professions Education and Patient Care by
Cover of the book Graph Transformation by
Cover of the book Coherent Structures in Granular Crystals by
Cover of the book Measurement of Quarkonium Polarization to Probe QCD at the LHC by
Cover of the book The Neoliberalization of Creativity Education by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy